All In Biotech

Drug Trial Radar · NCT01839487

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Jul 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

279

Actual

Start

May 14, 2013

Primary completion

May 1, 2018

Study completion Sep 26, 2018

Sponsor

Lead sponsor
Halozyme TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) \[PAG\] to NAB and GEM \[AG\] in participants with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). The study will have 2 run-in phases, one for each formulation of PEGPH20 (original and new formulations), and a Phase 2 portion. The 2 run-in phases will evaluate the safety and tolerability of the PAG treatment using the original and new succinic acid PEGPH20 formulation, respectively, compared with AG treatment. Phase 2 will have 2 stages due to a partial clinical hold that occurred from April through July 2014. The participants will be randomized in 3:1 for the run-in phases. The first stage will randomize participants in a 1:1 ratio. The second stage will randomize participants in a 2:1 ratio (PAG:AG). This is an open-label study. To minimize bias to the progression-free survival endpoint, disease progression will be based on the assessment of the Central Imaging Reader (CIR). Determination of clinical progression by the Investigator without corresponding CIR confirmation will be documented with the relevant signs and symptoms.

Conditions

  • Metastatic Pancreatic Cancer

Interventions

  • PEGPH20Drug

    PEGPH20 will be administered as per the dose and schedule specified in the respective arms.

  • Nab-paclitaxelDrug

    Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.

  • GemcitabineDrug

    Gemcitabine will be administered as per the dose and schedule specified in the respective arms.

  • DexamethasoneDrug

    Dexamethasone will be administered as per the dose and schedule specified in the respective arms.

  • EnoxaparinDrug

    Enoxaparin will be administered as per the dose and schedule specified in the respective arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From the date of randomization until disease progression or death from any cause (maximum exposure: 30.72 months for PAG, and 20.27 months for AG)
  2. Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the StudyTime frame: From first exposure to any study drug (PEGPH20, NAB, GEM) through 30 days after end of treatment visit (maximum exposure: 30.72 months for PAG)

Locations

51 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Oncology

    Birmingham, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Clinic - Scottsdale

    Scottsdale, Arizona

  • Arizona Oncology Associates, PC

    Tucson, Arizona

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Providence St Joseph Medical Center

    Burbank, California

  • Scripps Cancer Center

    La Jolla, California

  • UCSD - Moore's Cancer Center

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California Medical Center

    Orange, California

  • Pacific Hematology Oncology Associates

    San Francisco, California

  • Saint Helena Hospital

    St. Helena, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • Stamford Hospital

    Stamford, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of Miami, Sylvester comprehensive Cancer Center

    Miami, Florida

  • H. Lee Moffit Cancer Center

    Tampa, Florida

  • Piedmont Hospital

    Atlanta, Georgia

  • Loyola University Medical Center

    Maywood, Illinois

  • Norton Cancer Institute - Norton HealthCare Pavilion

    Louisville, Kentucky

  • Johns Hopkins University Hospital

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Lahey Clinic

    Burlington, Massachusetts

  • University of Mass Medical School

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Virginia Piper Cancer Institute

    Minneapolis, Minnesota

  • Unniversity of Minnesota

    Minneapolis, Minnesota

  • Research Medical Center

    Kansas City, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • St. Joseph's Regional Medical Center

    Paterson, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • North Shore Long Island Jewish Health System

    Lake Success, New York

  • Mount Sinai Medical Center

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Gabrail Cancer Center

    Canton, Ohio

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.